RDHL vs PTGX

For growth investors, RedHill Biopharma Ltd.

(RDHL) is the stronger pick with 23. 2% revenue growth year-over-year, versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). Analysts rate Protagonist Therapeutics, Inc. (PTGX) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Protagonist Therapeutics, Inc.

(PTGX) delivered a total return of +251. 2%, compared to -100. 0% for RedHill Biopharma Ltd. (RDHL). Over 10 years, the gap is even starker: PTGX returned +749. 2% versus RDHL's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Protagonist Therapeutics, Inc.

(PTGX) is the lower-risk stock at 0. 23β versus RedHill Biopharma Ltd. 's 1. 30β — meaning RDHL is approximately 459% more volatile than PTGX relative to the S&P 500.

By revenue growth (latest reported year), RedHill Biopharma Ltd.

(RDHL) is pulling ahead at 23. 2% versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). On earnings-per-share growth, the picture is similar: RedHill Biopharma Ltd. grew EPS -115. 2% year-over-year, compared to -148. 5% for Protagonist Therapeutics, Inc.. Over a 3-year CAGR, PTGX leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

RedHill Biopharma Ltd.

(RDHL) is the more profitable company, earning -102. 8% net margin versus -282. 8% for Protagonist Therapeutics, Inc. — meaning it keeps -102. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RDHL leads at -181. 7% versus -343. 6% for PTGX. At the gross margin level — before operating expenses — PTGX leads at 97. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Protagonist Therapeutics, Inc.

(PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 23), +749. 2% 10Y return). Both have compounded well over 10 years (PTGX: +749. 2%, RDHL: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RDHL is a small-cap high-growth stock; PTGX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.